[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced--metastatic-solid-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced--metastatic-solid-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100627975","phase-1-study-of-abo2102-in-kras-mutated-solid-tumors-100627975",false,"NCT07455617","Study of ABO2102 in KRAS-Mutated Solid Tumors","A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of ABO2102 in Participants With KRAS Mutant Solid Tumors","Inclusion Criteria:\n\n1. ≥18 years of age at time of informed consent.\n2. Have a genetically tested report confirmed by the investigator or complete genetic testing during the screening period, with evidence of harboring any of required KRAS mutations\n3. Histopathologically and\u002For cytologically confirmed locally advanced or metastatic solid tumors.\n4. According to RECIST v1.1, at least one measurable lesion is required.\n5. No severe hematological, hepatic, renal or coagulation dysfunction; laboratory test results during the screening period must meet the respective criteria specified in the study protocol.\n6. Females of childbearing potential and males who are involved in heterosexual activity must agree to practice highly effective contraception.\n\nExclusion Criteria:\n\n1. Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that have been cured, superficial bladder cancer, or carcinoma in situ of the breast or cervix.\n2. Has known symptomatic central nervous system (CNS) metastases, or CNS metastases requiring local CNS-directed therapy .\n3. Received KRAS cancer vaccine before.\n4. History of severe (≥ Grade 3) hypersensitivity reactions to immunotherapy.\n5. History of allogeneic organ transplantation or graft-versus-host disease (GVHD).\n6. Any active infection (except for hepatitis virus infection) requires systemic treatment.\n7. Absence of spleen\n8. Known psychiatric disorder or drug abuse that may interfere with the trial requirements\n9. Participant is pregnant or breastfeeding or expecting to conceive within the projected duration of the study.\n10. Other conditions that Investigators consider inappropriate for enrollment.","ALL","18 Years",{"count":19,"type":20},101,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.",[26],"Advanced \u002F Metastatic Solid Tumor","RECRUITING","2026-04-03",{"date":30,"type":31},"2026-04-06","ACTUAL",{"date":33,"type":31},"2026-03-24",{"date":35,"type":20},"2030-02",{"name":37,"class":38},"Suzhou Abogen Biosciences Co., Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100520985","phase-1-a-study-of-sr-8541a-enppi-inhibitor-in-advancedmetastatic-solid-tumors-100520985","NCT06063681","A Study of SR-8541A (ENPPI Inhibitor) in Advanced\u002FMetastatic Solid Tumors","Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Life expectancy of at least 3 months\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1\n3. Histopathologically\u002Fcytologically confirmed advanced solid tumor, which is refractory to standard therapeutic options, or for which there are no standard therapeutic options.\n4. Measurable disease per RECIST v1.1\n5. Willing to provide archival or fresh tumor tissue during screening (required) and post-treatment (optional)\n6. Adequate hematologic, renal and hepatic function\n\nExclusion Criteria:\n\n1. Primary central nervous system (CNS) tumor\n2. Prior systemic anti-cancer treatment including other investigational agents, surgery, or radiation within 28 days or 5 half-lives, whichever is less\n3. Continuous systemic treatment with either corticosteroids (\\>10 milligram \\[mg\\] daily prednisone equivalents) or other immunosuppressive medications within 28 days\n4. Active autoimmune disease that has required systemic treatment in past 2 years\n5. History of documented congestive heart failure (New York Heart Association \\[NYHA\\] class II - IV); unstable angina; poorly controlled hypertension; clinically significant valvular heart disease; high-risk uncontrolled arrhythmias (including sustained ventricular tachycardia); myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within the last 6 months, or Canadian Cardiovascular Society angina class \\> 2\n6. Troponin I \\> ULN\n7. Blood pressure (BP) - Systolic \\\u003C 95 mmHg or \\> 160 mmHg or diastolic \\> 100 mmHg\n8. Resting heart rate (HR) \\> 100 beats per minute (BPM)\n9. Corrected QT interval by Fridericia (QTcF) ≥ 470 ms\n10. Left Ventricular Ejection Fraction (LVEF) \\\u003C 50%\n11. Symptomatic uncontrolled CNS disease requiring treatment with steroids or anti-seizure medications within 2 months\n12. Leptomeningeal disease\n13. Spinal cord compression not definitively treated with surgery and\u002For radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 8 weeks\n14. Bleeding diathesis due to underlying medical condition or anticoagulation medication which is unable to be promptly reversed by medical treatment\n15. Prior additional malignancy that is progressing or has received treatment the previous 3 years\n16. Active infection requiring systemic treatment\n17. Positive for human immunodeficiency virus (HIV) (HIV antibodies) or active hepatitis B (e.g., HbsAg reactive) or active hepatitis C (e.g., HCV ribonucleic acid \\[RNA\\] qualitative) infection with detectable viral load\n18. Major surgery within 28 days prior to Day 1 and\u002For minor surgery (excluding biopsy) within 7 days",{"count":48,"type":20},25,[23],"This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.",[26],[53,54,55],"Refractory","Relapsing","Solid Tumors","2025-06-04",{"date":58,"type":31},"2025-06-08",{"date":60,"type":31},"2023-10-12",{"date":62,"type":20},"2025-12",{"name":64,"class":38},"Stingray Therapeutics",3]